FDA warning letters are sending a clear message: promotional claims that exaggerate benefits or hide risks won’t go unchecked. Recent actions against major drugmakers and digital advertisers show how quickly misleading statements can escalate into regulatory scrutiny, market fallout, and investor exposure.